Seema Singhal

Grants

Grants per year 2003 2003 2005 2006 2007 2010 2021 2022 2027

• 11 Active
• 51 Finished

Grants per year

Search results

• Active

  Prot #CA0881000: A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

  Singhal, S. (PD/PI)

  Juno Therapeutics, Inc.

  10/11/24 → 10/11/27

  Project: Research project

• Prot #68284528MMY4006: Intermediate‐Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta‐cel) Out‐of‐Specification (OOS) in patients with Multiple Myeloma

  Singhal, S. (PD/PI)

  Janssen Research & Development, LLC

  7/19/23 → 7/19/26

  Project: Research project

• Prot #68284528MMY4002: Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel

  Singhal, S. (PD/PI)

  Parexel, Janssen Research & Development, LLC

  3/20/23 → 3/20/26

  Project: Research project

• Prot #TAK-573-1501: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma

  Singhal, S. (PD/PI)

  Pharmaceutical Research Associates, Inc., Takeda Development Center Americas, Inc.

  12/8/22 → 12/8/25

  Project: Research project

• Prot #68284528MMY2005: A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients with Multiple Myeloma

  Singhal, S. (PD/PI)

  Janssen Research & Development, LLC

  5/25/22 → 12/8/25

  Project: Research project

• Prot #ALLO-605-201: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients with Relapsed/Refractory Multiple Myelom

  Singhal, S. (PD/PI)

  Covance Inc., Allogene Therapeutics, Inc.

  2/1/22 → 2/1/25

  Project: Research project

• Prot #BB2121-EAP-001: Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming for Commercial Release

  Singhal, S. (PD/PI)

  DrugDev Inc., Celgene Corporation

  12/8/20 → 1/30/26

  Project: Research project

• Prot #68284528MMY2003: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2)

  Singhal, S. (PD/PI)

  Janssen Research & Development, LLC

  2/11/20 → 2/11/26

  Project: Research project

• Prot #CC-92480-MM-002: A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory

  Singhal, S. (PD/PI)

  Celgene Corporation

  11/14/19 → 11/14/25

  Project: Research project

• Prot #CC-220-MM-001: A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 Monotherapy and in Combination with Other Treatments in Sub

  Singhal, S. (PD/PI)

  ICON Clinical Research, LLC, Celgene Corporation

  10/10/19 → 10/10/25

  Project: Research project

• Prot #BB2121-MM-003: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare The Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

  Singhal, S. (PD/PI)

  Celgene Corporation

  7/17/19 → 7/17/25

  Project: Research project

• Finished

  NU 22H01: Serial Monitoring of Circulating Plasma Cells and Plasma Cell Components in Adults with Plasma Cell Disorders

  Singhal, S. (PD/PI) & Singhal, S. (PD/PI)

  Menarini Silicon Biosystems, Inc.

  6/1/22 → 12/31/23

  Project: Research project

  • Circulating Plasma Cells 100%
  • Serial Monitoring 100%
  • Cell Components 100%
  • Cell-to-cell 100%
  • Plasma Cell Disorders 100%

• Prot #BB2121-MM-007: An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Relapsed/Refractory Multiple Myeloma (KarMMa-7)

  Singhal, S. (PD/PI)

  DrugDev Inc., Celgene Corporation

  8/6/21 → 8/6/24

  Project: Research project

• Prot #C1071003: MAGNETISMM-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and On

  Singhal, S. (PD/PI)

  Pfizer Inc.

  7/21/21 → 7/21/24

  Project: Research project

• Prot #209627: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)

  Singhal, S. (PD/PI)

  Quintiles, Inc., GlaxoSmithKline LLC

  3/12/21 → 3/12/24

  Project: Research project

• Prot #209626: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)

  Singhal, S. (PD/PI)

  Quintiles, Inc., GlaxoSmithKline LLC

  3/10/21 → 3/10/24

  Project: Research project

• Prot #213304: Expanded Access Program for Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody

  Singhal, S. (PD/PI)

  Quintiles, Inc., GlaxoSmithKline LLC

  3/11/20 → 3/11/23

  Project: Research project

• Prot #MK-3475-183: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM).

  Singhal, S. (PD/PI)

  Merck Sharp & Dohme Corporation

  1/26/17 → 1/26/20

  Project: Research project

• Prot #NEOD001-CL002: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

  Singhal, S. (PD/PI)

  Covance Inc., Prothena Therapeutics Limited

  12/11/15 → 12/11/18

  Project: Research project

• Prot #54767414MMY3010: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to

  Singhal, S. (PD/PI)

  Janssen Research & Development, LLC

  10/23/15 → 10/23/18

  Project: Research project

• Prot #ARRAY-520-215:A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

  Singhal, S. (PD/PI)

  ICON Clinical Research, LLC, Array BioPharma Incorporated

  5/5/15 → 5/5/18

  Project: Research project

• Prot #M12-901: A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects who are Receiving Bortezomib and Dexamethasone as their Standard Therapy

  Singhal, S. (PD/PI)

  AbbVie Inc.

  9/25/14 → 9/25/17

  Project: Research project

• Prot #ARRAY-520-216: A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma

  Singhal, S. (PD/PI)

  Array BioPharma Incorporated

  5/29/14 → 5/29/17

  Project: Research project

• Prot #54767414MMY2002: An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are

  Singhal, S. (PD/PI)

  Janssen Research & Development, LLC

  10/10/13 → 10/10/16

  Project: Research project

• Prot #FRF4998g: An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients with Relapsed or Refractory Multiple Myeloma.

  Singhal, S. (PD/PI)

  Genentech, Inc

  1/13/12 → 1/13/18

  Project: Research project